Retatrutide, a new dual activator of the GLP-1 binding site and glucose-dependent secreted polypeptide (GIP) binding site , is showing promising data in early human studies. Recent research suggests that retatrutide may offer significant benefits for individuals with type , particularly regarding weight reduction and blood sugar control . Further e